2
Orphan Designations
0 approved, 2 designated
0
FDA Approvals
1
Active Trials
200 recruiting
2
Rare Diseases
across 4 areas
1
News (30d)
Rezolute Inc. is a company with 2 orphan drug designations across 2 rare diseases. Active clinical trials in 1 indication. 1 news article in the past 30 days.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| congenital isolated hyperinsulinism | fully human IgG2 monoclonal antibody that binds insulin receptors | Des.TrialAppr. |
| sarcoma | - | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
0
overlap in 2+ diseases
0/2
candidate diseases
1
avg importance: 70
0
affecting portfolio
0% of portfolio targets high unmet need diseases
0
overlap in 2+ diseases
0/2
candidate diseases
1
avg importance: 70
0
affecting portfolio